Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvalent, Inc. filings document a clinical-stage oncology company developing small-molecule inhibitors for clinically proven kinase targets. Its Form 8-K reports disclose operating and financial results, pipeline and clinical-trial updates for zidesamtinib and neladalkib, FDA submission events, material-event disclosures, and royalty or revenue-share arrangements for its investigational product candidates.
Proxy materials cover annual meeting governance, executive compensation, equity awards, and shareholder voting matters. Other disclosures describe Nuvalent's Class A common stock, capital-structure matters, research and development spending, cash resources, and regulatory considerations associated with advancing ROS1-, ALK-, and HER2-directed cancer programs.
Nuvalent, Inc.’s Chief Development Officer, Darlene Noci, reported an options exercise and related share sales. On January 29, 2026, she exercised 5,500 stock options at $27.85 per share, receiving the same number of Class A common shares.
That same day she sold portions of Class A common stock in several trades: 189 shares at $100.95, 3,429 shares at $101.8, 1,819 shares at $102.67, and 63 shares at $103.39, with prices reported as weighted averages. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 18, 2024.
After the reported transactions, Noci directly held 58,117 shares of Class A common stock and 108,829 stock options. The option underlying the 5,500-share exercise vests in equal monthly installments over four years following January 6, 2023, subject to continued service.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported option exercises and share sales under a pre-arranged trading plan. On January 21, 2026 she exercised 700 stock options at an exercise price of $27.85 per share and sold 700 shares of Class A common stock at a weighted average price of $109.84 per share, leaving 59,634 shares owned directly. On January 22, 2026 she exercised an additional 14,300 options at $27.85 per share and sold 14,300 shares at a weighted average price of $110.16 per share, again leaving 59,634 shares owned directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024, and the underlying options vest in equal monthly installments over four years following January 6, 2023, subject to continued service.
Nuvalent insider Deborah Miller has filed a Form 144 notice to sell up to 21,000 shares of Nuvalent common stock. The shares are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of 01/22/2026. The filing notes that 67,271,461 common shares were outstanding.
The 21,000 shares were acquired on 01/22/2026 via a cash exercise of stock options from the issuer. The notice also lists recent sales of Nuvalent common stock over the past three months, including 24,200 shares sold on 11/17/2025 and 21,800 shares sold on 10/30/2025, some under Rule 10b5-1 trading arrangements. By signing, the seller represents that she is not aware of undisclosed material adverse information about the company.
Nuvalent, Inc. furnished an update indicating that it preliminarily estimates having approximately $1.4 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is described as a preliminary, unaudited estimate as of January 12, 2026 and may change once year-end financial closing procedures are completed, so it does not provide a full picture of the company’s financial condition at that date. The estimate was disclosed via a press release attached as Exhibit 99.1, which is being furnished rather than filed, and the company notes that related statements are forward-looking and subject to risks outlined in its prior SEC reports.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported a mix of stock sales and new equity awards. On January 5–6, 2026, he sold multiple blocks of Nuvalent Class A Common Stock in open-market transactions, including 513 shares at a weighted average price of $96.06, 660 shares at $96.85, 1,137 shares at $97.96, 186 shares at $98.52, 1,106 shares at $96.75, 1,369 shares at $97.33 and 189 shares at $98.40.
According to the footnotes, these sales were made under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations on vesting equity awards. On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock for $0.00 pursuant to restricted stock units that vest in three equal annual installments after January 7, 2026, and received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported several sales and equity awards involving the company’s Class A Common Stock. On January 5 and 6, 2026, she sold multiple small blocks of shares under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations upon vesting of earlier equity awards. Reported weighted average sale prices include $96.06, $96.85, $97.96 and $98.52 per share.
On January 7, 2026, Noci reported an acquisition of 17,500 Class A shares for $0.00 per share, representing restricted stock units that vest in three equal annual installments following that date, subject to continued service. She also received a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026. Following these transactions, she directly owned 58,117 Class A shares and 17,500 stock options.
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported multiple transactions in the company’s Class A Common Stock. On January 5–6, 2026, she sold several small blocks of shares at weighted average prices generally ranging from about $95.34 to $99.10 per share, with the filing noting these sales were made under a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations on previously granted equity awards.
On January 7, 2026, she received 17,500 restricted stock units (RSUs), each representing one share of Class A Common Stock, which vest in three equal annual installments following that date, and a stock option for 17,500 shares at an exercise price of $106.82 that vests in equal monthly installments over four years. After these transactions, she directly beneficially owned 59,634 shares of Class A Common Stock and 17,500 stock options.
Nuvalent, Inc. Chief Medical Officer Christopher Durant Turner reported multiple sales of Class A common stock on January 5–6, 2026, at weighted average prices generally in the $96–$99 range. The filing notes these sales were executed under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to cover tax withholding on previously vested equity awards.
On January 7, 2026, he reported the acquisition of 17,500 restricted stock units (RSUs), each representing one share of Class A common stock, which vest in three equal annual installments following January 7, 2026, subject to continued service. He also received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years following January 7, 2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported several transactions in the company’s Class A common stock. On January 5 and 6, 2026, she sold small blocks of shares at weighted average prices ranging from about $95 to $99 per share under a durable Rule 10b5-1 sell-to-cover instruction, used to satisfy tax withholding on previously granted equity awards. After these sales, she continued to hold tens of thousands of shares directly.
On January 7, 2026, Balcom received 17,500 restricted stock units, each representing one share of Nuvalent Class A common stock. These RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. She was also granted a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years following January 7, 2026, also conditioned on continued service.
Nuvalent, Inc. President and CEO James Richard Porter reported multiple stock transactions in early January 2026. On January 5–6, 2026, he sold several blocks of Nuvalent Class A Common Stock under a pre-arranged Rule 10b5-1 sell-to-cover instruction, with weighted average prices ranging from about $96 to $99 per share to cover tax withholding on previously vested equity awards. After these sales, his directly held shares were reduced to 278,629.
On January 7, 2026, Porter received 46,250 restricted stock units (RSUs) for Class A Common Stock at a stated price of $0.00, increasing his directly held shares to 324,879. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. He was also granted a stock option for 46,250 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026.